Brand biologics grab 12 years' exclusivity, for now

The 12-year data exclusivity for innovator biologic drugs voted for by the Senate committee in July marks a victory of sorts for biotech industry lobbyists. But the 167 vote by the US Senate Health, Education, Labor, and Pensions Committee is hardly the end of the industry's efforts to hold the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2009-08, Vol.27 (8), p.677-678
1. Verfasser:	Osborne, Randy
Format:	Artikel
Sprache:	eng
Schlagworte:	Agriculture Bioinformatics Biological products Biological Products - economics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Biotechnology - economics Biotechnology industry Congressional committees Drug Industry - economics Drugs, Generic - economics Federal Government Generic drugs Life Sciences Management news Political aspects Time Factors United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The 12-year data exclusivity for innovator biologic drugs voted for by the Senate committee in July marks a victory of sorts for biotech industry lobbyists. But the 167 vote by the US Senate Health, Education, Labor, and Pensions Committee is hardly the end of the industry's efforts to hold the line against biogenerics.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt0809-677